Abstract
Given its myeloid-restricted expression, myeloperoxidase (MPO) is typically used for lineage assignment (myeloid vs. lymphoid) during acute leukaemia (AL) diagnostics. In the present study, a robust flow cytometric definition for MPO positivity was established based on the standardised EuroFlow protocols, the standardised Acute Leukaemia Orientation Tube and 1734 multicentre AL cases (with confirmed assay stability). The best diagnostic performance was achieved by defining MPO positivity as ≥20% of the AL cells exceeding a lymphocyte-based threshold. The methodology employed should be applicable to any form of standardised flow cytometry.
Original language | English |
---|---|
Pages (from-to) | 922-927 |
Number of pages | 6 |
Journal | British Journal of Haematology |
Volume | 193 |
Issue number | 5 |
Early online date | 7 Nov 2020 |
DOIs | |
Publication status | Published - Jun 2021 |
Bibliographical note
Funding Information:We gratefully acknowledge all clinicians participating in this study for providing patient material and clinical data. We gratefully thank all technicians of the Laboratory Medical immunology for their support. The research for this manuscript was performed within the framework of the Erasmus Postgraduate School Molecular Medicine. The co‐ordination of this study was supported by the EuroFlow Consortium. The EuroFlow Consortium received support from the FP6‐2004‐LIFESCIHEALTH‐5 programme of the European Commission (grant LSHB‐CT‐2006‐018708) as Specific Targeted Research Project (STREP). The EuroFlow Consortium is part of the European Scientific Foundation for Hemato‐Oncology (ESLHO), a Scientific Working Group (SWG) of the European Hematology Association (EHA).
Funding Information:
We gratefully acknowledge all clinicians participating in this study for providing patient material and clinical data. We gratefully thank all technicians of the Laboratory Medical immunology for their support. The research for this manuscript was performed within the framework of the Erasmus Postgraduate School Molecular Medicine. The co-ordination of this study was supported by the EuroFlow Consortium. The EuroFlow Consortium received support from the FP6-2004-LIFESCIHEALTH-5 programme of the European Commission (grant LSHB-CT-2006-018708) as Specific Targeted Research Project (STREP). The EuroFlow Consortium is part of the European Scientific Foundation for Hemato-Oncology (ESLHO), a Scientific Working Group (SWG) of the European Hematology Association (EHA).
Publisher Copyright:
© 2020 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.